Evidence map›Paper›PMID 31501272›Full record

ArticleThe oncologist2020

Cost and Utilization of Lung Cancer End-of-Life Care Among Racial-Ethnic Minority Groups in the United States.

Yufan Chen, Steven D Criss, Tina R Watson, Andrew Eckel, Lauren Palazzo, Angela C Tramontano, Ying Wang, Nathaniel D Mercaldo, Chung Yin Kong

Open access · bronzeAbstract read
In one paragraph

Article in The oncologist, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
3.6field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Financial hardship experience in middle- and older-aged patients with advanced lung cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Trial
  3. Article
  4. Racial and Ethnic Disparities in Intensity of Care at the End of Life for Patients With Lung Cancer: A 13-Year Population-Based Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yufan ChenInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-3501-9807
Steven D CrissInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0002-9394-1381
Tina R WatsonInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
Andrew EckelInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
Lauren PalazzoInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.
Angela C TramontanoInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-5718-6297
Ying WangBC Cancer Vancouver, Vancouver, British Columbia, Canada.
Nathaniel D MercaldoInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0003-1658-6598
Chung Yin KongInstitute for Technology Assessment, Massachusetts General Hospital, Boston, Massachusetts, USA.ORCID 0000-0001-6431-7830
Massachusetts General Hospital · US

Funding

Comparative Modeling of Lung Cancer Prevention and Control PoliciesU01CA199284 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE KONING, HARRY J, HOLFORD, THEODORE R · 2015 to 2019
$8.4M
Optimizing Treatment of Lung Cancer Patients with ComorbiditiesR01CA202956 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KONG, CHUNG YIN, WISNIVESKY, JUAN P · 2016 to 2019
$2.9M
NCI NIH HHS R01 CA202956NCI NIH HHS R01CA202956NCI NIH HHS U01 CA199284NCI NIH HHS U01CA199284
6 · The paper itself

Abstract

backgroundThe end-of-life period is a crucial time in lung cancer care. To have a better understanding of the racial-ethnic disparities in health care expenditures, access, and quality, we evaluated these disparities specifically in the end-of-life period for patients with lung cancer in the U.S. MATERIALS AND

methodsWe used the Surveillance, Epidemiology, and End Results (SEER)-Medicare database to analyze characteristics of lung cancer care among those diagnosed between the years 2000 and 2011. Linear and logistic regression models were constructed to measure racial-ethnic disparities in end-of-life care cost and utilization among non-Hispanic (NH) Asian, NH black, Hispanic, and NH white patients while controlling for other risk factors such as age, sex, and SEER geographic region.

resultsTotal costs and hospital utilization were, on average, greater among racial-ethnic minorities compared with NH white patients in the last month of life. Among patients with NSCLC, the relative total costs were 1.27 (95% confidence interval [CI], 1.21-1.33) for NH black patients, 1.36 (95% CI, 1.25-1.49) for NH Asian patients, and 1.21 (95% CI, 1.07-1.38) for Hispanic patients. Additionally, the odds of being admitted to a hospital for NH black, NH Asian, and Hispanic patients were 1.22 (95% CI, 1.15-1.30), 1.47 (95% CI, 1.32-1.63), and 1.18 (95% CI, 1.01-1.38) times that of NH white patients, respectively. Similar results were found for patients with SCLC.

conclusionMinority patients with lung cancer have significantly higher end-of-life medical expenditures than NH white patients, which may be explained by a greater intensity of care in the end-of-life period. IMPLICATIONS FOR PRACTICE: This study investigated racial-ethnic disparities in the cost and utilization of medical care among lung cancer patients during the end-of-life period. Compared with non-Hispanic white patients, racial-ethnic minority patients were more likely to receive intensive care in their final month of life and had statistically significantly higher end-of-life care costs. The findings of this study may lead to a better understanding of the racial-ethnic disparities in end-of-life care, which can better inform future end-of-life interventions and help health care providers develop less intensive and more equitable care, such as culturally competent advanced care planning programs, for all patients.

Indexed as

AgedEthnicityFemaleHumansLung NeoplasmsMaleMinority GroupsTerminal CareUnited StatesRacial-ethnic disparity • Lung cancer • End-of-life care • Cost and utilization

Identifiers

PMID31501272
PMCPMC6964141
OpenAlexW2972608435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.